PTC Therapeutics officer sells 3,121 shares for taxes

PTC Therapeutics chief technical operations officer Neil Gregory Almstead reported automatic stock sales to cover taxes tied to restricted stock unit vesting.

Rhea-AI Filing Summary

PTC Therapeutics chief technical operations officer Neil Gregory Almstead reported automatic stock sales to cover taxes tied to restricted stock unit vesting. On February 18, he sold 3,121 shares of common stock at $69.36 per share, including 3,056 shares held directly and 65 shares held indirectly through his spouse.

These transactions were executed under irrevocable sell-to-cover elections made when the RSU grants were accepted, to satisfy tax withholding obligations. After these sales, Almstead held 112,140 shares directly and 6,726 shares indirectly through his spouse.

Insider Trade Summary

Net Seller: 3,121 shares

Net Sell 2 txns

Insider Almstead Neil Gregory

Role CHIEF TECHNICAL OPS OFFICER

Sold 3,121 shs ($216K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,056	$69.36	$212K
Sale	Common Stock	65	$69.36	$5K

Holdings After Transaction: Common Stock — 112,140 shares (Direct); Common Stock — 6,726 shares (Indirect, By Spouse)

Footnotes (2)

1. F1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,750 RSUs from a February 15, 2024 grant of 19,000 RSUs and the vesting of 3,000 RSUs from a February 15, 2024 grant of 6,000 RSUs.
2. F2. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 217 RSUs from a February 15, 2024 grant of 870 RSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transactions did PTCT officer Neil Gregory Almstead report?

Neil Gregory Almstead reported automatic sales of 3,121 PTC Therapeutics shares. The trades occurred on February 18 at $69.36 per share to cover tax withholding from vesting restricted stock units under pre-set sell-to-cover elections.

Were Neil Gregory Almstead’s PTCT share sales discretionary or tax-related?

The reported PTCT share sales were tax-related, not discretionary. Footnotes state they were automatic sales under irrevocable sell-to-cover elections to satisfy tax withholding obligations from the vesting of multiple restricted stock unit grants.

How many PTC Therapeutics shares did Almstead sell and at what price?

Almstead sold a total of 3,121 PTC Therapeutics common shares. The transactions included 3,056 directly held shares and 65 indirectly held through his spouse, all executed at a price of $69.36 per share on February 18.

How many PTCT shares does Neil Gregory Almstead hold after these transactions?

After the reported transactions, Almstead holds 112,140 PTCT shares directly. He also has indirect ownership of 6,726 shares through his spouse, according to the ownership balances disclosed following the February 18 tax-related sales.

What RSU vesting events triggered Almstead’s PTCT tax-withholding sales?

The sales were tied to vesting from several February 15, 2024 RSU grants. Footnotes reference 4,750 and 3,000 RSUs vesting from larger grants, plus 217 RSUs from another grant, all requiring tax withholding funded by share sales.

Does Almstead’s spouse’s PTCT stock appear in the Form 4 transactions?

Yes, 65 of the sold shares were held indirectly through Almstead’s spouse. The filing labels this as indirect ownership "By Spouse," and these shares were also sold under the tax-related, irrevocable sell-to-cover election for RSU vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Almstead Neil Gregory

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNICAL OPS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		S		3,056(1)	D	$69.36	112,140	D
Common Stock	02/18/2026		S		65(2)	D	$69.36	6,726	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,750 RSUs from a February 15, 2024 grant of 19,000 RSUs and the vesting of 3,000 RSUs from a February 15, 2024 grant of 6,000 RSUs.

2. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 217 RSUs from a February 15, 2024 grant of 870 RSUs.

	/s/ Avraham S. Adler, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.